Clinical Trials Logo

Acute Myeloid Leukemia (AML) clinical trials

View clinical trials related to Acute Myeloid Leukemia (AML).

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT03070093 Approved for marketing - Clinical trials for Acute Myeloid Leukemia (AML)

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission with incomplete hematologic recovery [CRi], complete remission with incomplete platelet recovery [CRp]) with MRD without access to comparable or alternative therapy.